Independent Judgment Built Through Consequence

MolecPath Innovations exists for situations where decisions carry real consequence—capital at risk, credibility on the line, and limited opportunity to reverse course.

The firm is led by Scott Donovan, a diagnostics and pathology executive with more than two decades of experience operating at the intersection of science, regulation, and commercialization. His work has spanned global manufacturers, emerging platforms, and clinical laboratories, across moments of growth, transition, and constraint.

Scott’s perspective was shaped inside organizations where decisions could not be abstracted or delegated. Capital deployment, portfolio direction, regulatory posture, and commercial strategy were not theoretical exercises—they determined outcomes.

• Leading and advising across molecular diagnostics, anatomic pathology, cytogenetics, and advanced staining 
• Operating within regulated environments where scientific ambition must align with regulatory reality 
• Working across commercial, technical, and leadership functions where internal alignment is rarely automatic
   

The result is an ability to evaluate not just what could work, but what is likely to survive real-world conditions.